News
OTLKW
0.0300
0.00%
0.00
Outlook Therapeutics® to Present at the Retina World Congress 2024
Outlook Therapeutics, Inc. Will present at the 2024 Retina World Congress being held May 9-12, 2024 in Fort Lauderdale, FL. The company is working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases.
Barchart · 2d ago
OUTLOOK THERAPEUTICS® ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF $5.0 MILLION
Reuters · 04/15 20:15
OUTLOOK THERAPEUTICS - FILES PROSPECTUS SUPPLEMENT RELATED TO OFFER, SALE OF UP TO $93.7 MLN OF COMMON STOCK THAT MAY BE SOLD UNDER SALES AGREEMENT
Reuters · 04/12 20:30
GREAT POINT PARTNERS, LLC REPORTS 9.99% PASSIVE STAKE IN OUTLOOK THERAPEUTICS AS OF APRIL 1- SEC FILING
Reuters · 04/08 20:13
OUTLOOK THERAPEUTICS INC - ON APRIL 1, RECEIVED WRITTEN NOTICE FROM NASDAQ INFORMING COMPANY THAT IT HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE
Reuters · 04/02 20:17
BUZZ-U.S. STOCKS ON THE MOVE-Reddit, Alphabet, Tesla
The blue-chip Dow and the benchmark S&P 500 eased on Friday, but are still on track for strong weekly gains. Investors cheered the Federal Reserve's rate-easing stance. Reddit, Alphabet and Tesla were among the biggest losers on Wall Street. The Dow Jones Industrial Average was down 0.46% and the Nasdaq Composite was up.
Reuters · 03/22 17:59
BUZZ-U.S. STOCKS ON THE MOVE-Best Buy, Summit Midstream, Outlook Therapeutics
Wall Street's main stock indexes struggle for direction on Friday. Dow Jones Industrial Average down 0.43% but on track for strong weekly gains. Top three S&P 500 percentage gainers: Fedex Corp, Nvidia, Outlook Therapeutics. Best Buy, Summit Midstream, Tesla among the top U.S. Stocks on the move.
Reuters · 03/22 16:15
BUZZ-Outlook Therapeutics soars as EU drug regulator backs its eye disease drug
Outlook Therapeutics shares rise 35.6% to $9.58 after EU drug regulator backs its eye disease drug. European Commission expected to make a decision on drug's approval within 67 days. Outlook's drug is for a type of eye disease called wet age-related macular degeneration.
Reuters · 03/22 14:09
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Outlook Therapeutics, Inc. Is working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU. The company has closed its previously announced private placement for $60 million in gross proceeds. Outlook has the potential to receive additional gross proceeds of up to $99 million.
Barchart · 03/18 16:10
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
Outlook Therapeutics, Inc. Is working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases. A 1-for-20 reverse stock split of its outstanding shares of common stock will be effective on March 14, 2024.
Barchart · 03/12 07:05
Outlook Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Outlook Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 4 cents per share; analysts expected a loss of 5 cents. Reported revenue was zero; analysts were expecting zero. Outlook Therapeutic Inc shares had risen by 23.0% this quarter.
Reuters · 02/19 14:36
Outlook Therapeutics Inc <OTLK.OQ> expected to post a loss of 5 cents a share - Earnings Preview
Outlook Therapeutics Inc expected to post a loss of 5 cents a share. The company is expected to show change in quarterly revenue when it reports results on May 13. The average analyst rating on the shares is "buy" and the median 12-month price target is $2.00.
Reuters · 02/16 14:00
BUZZ-U.S. STOCKS ON THE MOVE-United Airlines, AEON Biopharma, Plug Power
S&P 500 and the Nasdaq edged lower on Tuesday. The Dow dropped on the back of losses in 3M. United Airlines, AEON Biopharma and Plug Power were among the top gainers. The Nasdaq and the Dow Jones Industrial Average were both up.
Reuters · 01/23 18:27
BUZZ-Outlook Therapeutics up on receiving FDA nod for eye disease drug trial
Outlook Therapeutics' OTLK.O shares rise 15.5% to $0.39. Company says U.S. FDA gives approval for clinical trial testing of its experimental eye disease drug. Trial will enroll 400 patients with wet AMD, an eye disease. FDA in August 2023 declined to approve the drug.
Reuters · 01/23 15:58
Outlook Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Outlook Therapeutics Inc reports results for the quarter ended in September. The company reported a quarterly adjusted loss of 5 cents per share. The mean expectation of eight analysts was for the company to report a loss of 6 cents. The shares had risen by 101.8% this quarter and lost 58.7% this year.
Reuters · 12/27/2023 12:01
BUZZ-U.S. STOCKS ON THE MOVE-Palantir, Clorox, MercadoLibre
Reuters · 11/02/2023 13:22
BUZZ-U.S. STOCKS ON THE MOVE-Vera Bradley, Apple, Salesforce
Reuters · 08/30/2023 17:55
BUZZ-U.S. STOCKS ON THE MOVE-Energy firms, Gold miners, Tingo group
Reuters · 08/30/2023 15:51
BUZZ-U.S. STOCKS ON THE MOVE-Apple, Tingo, Abeona Therapeutics
Reuters · 08/30/2023 13:21
BUZZ-U.S. STOCKS ON THE MOVE-HP, Texas Instruments, Rite Aid
Reuters · 08/30/2023 11:59
More
Webull provides a variety of real-time OTLKW stock news. You can receive the latest news about Outlook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLKW
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.